Access the full text.
Sign up today, get DeepDyve free for 14 days.
Glassman Ar, Stock Cr, Beck Rw, C. Baker, Nguyen Qd, Brown Dm, Marcus Dm, Boyer Ds, Patel Feiner, Gibson Sy, Rundle Ac, Hopkins Jj, Rubio Rg, Js Ehrlich (2012)
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.Ophthalmology, 119 4
G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, M. Böhm, T. Christiaens, R. Cífková, G. Backer, A. Dominiczak, M. Galderisi, D. Grobbee, T. Jaarsma, P. Kirchhof, S. Kjeldsen, S. Laurent, A. Manolis, P. Nilsson, L. Ruilope, R. Schmieder, P. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad, M. Burnier, E. Ambrosioni, M. Caufield, A. Coca, M. Olsen, C. Tsioufis, P. Borne, J. Zamorano, S. Achenbach, H. Baumgartner, Jeroen Bax, H. Bueno, V. Dean, C. Deaton, Ç. Erol, R. Ferrari, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, P. Lancellotti, A. Linhart, P. Nihoyannopoulos, M. Piepoli, P. Ponikowski, J. Tamargo, M. Tendera, A. Torbicki, W. Wijns, S. Windecker, D. Clement, T. Gillebert, E. Rosei, S. Anker, J. Bauersachs, J. Hitij, M. Buyzere, S. Geest, G. Derumeaux, S. Erdine, C. Farsang, C. Funck-Brentano, V. Gerc, G. Germano, S. Gielen, H. Haller, J. Jordan, T. Kahan, M. Komajda, D. Lovic, H. Mahrholdt, J. Östergren, G. Parati, J. Perk, J. Polónia, B. Popescu, Ž. Reiner, L. Rydén, Y. Sirenko, A. Stanton, H. Struijker-Boudier, C. Vlachopoulos, M. Volpe, D. Wood (2013)
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).European heart journal, 34 28
J. Korobelnik, D. Do, U. Schmidt-Erfurth, D. Boyer, F. Holz, J. Heier, E. Midena, P. Kaiser, H. Terasaki, D. Marcus, Q. Nguyen, G. Jaffe, J. Slakter, C. Simader, Y. Soo, T. Schmelter, G. Yancopoulos, N. Stahl, R. Vitti, Alyson Berliner, O. Zeitz, C. Metzig, David Brown (2014)
Intravitreal aflibercept for diabetic macular edema.Ophthalmology, 121 11
J. Varon (2009)
The Diagnosis and Treatment of Hypertensive CrisesPostgraduate Medicine, 121
Hongxin Huang, Yayuan Zheng, Jianhong Zhu, Jingjing Zhang, Huapu Chen, Xinggui Chen (2014)
An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer PatientsPLoS ONE, 9
David Brown, Q. Nguyen, D. Marcus, D. Boyer, Sunil Patel, L. Feiner, P. Schlottmann, A. Rundle, Jiameng Zhang, Roman Rubio, A. Adamis, J. Ehrlich, J. Hopkins (2013)
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.Ophthalmology, 120 10
M. Vlcek, A. Bur, C. Woisetschläger, H. Herkner, A. Laggner, M. Hirschl (2008)
Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertensionJournal of Hypertension, 26
J. Farrar, James Young, L. Lamoreaux, J. Werth, R. Poole (2001)
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePAIN, 94
T. Ueta, Yasuo Noda, Taku Toyama, Takuhiro Yamaguchi, S. Amano (2014)
Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.Ophthalmology, 121 11
F. Scappaticci, J. Skillings, S. Holden, H. Gerber, K. Miller, F. Kabbinavar, E. Bergsland, J. Ngai, E. Holmgren, Jiuzhou Wang, H. Hurwitz (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.Journal of the National Cancer Institute, 99 16
N. Bressler, D. Boyer, David Williams, S. Butler, S. Francom, B. Brown, F. Nucci, Timothy Cramm, L. Tuomi, T. Ianchulev, Roman Rubio (2012)
CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALSRetina, 32
A. Glassman, Danni Liu, L. Jampol, Jennifer Sun (2018)
Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular EdemaInvestigative Ophthalmology & Visual Science, 59
Key PointsQuestionIs there an increase of blood pressure during intravitreal injections? FindingsIn this prospective study, there was a substantial increase in systolic blood pressure during intravitreal injections in some individuals. About 10% of patients had systolic blood pressure rise to greater than 200 mm Hg. MeaningBecause systolic blood pressure can become substantially elevated during intravitreal injections, future work may be needed to determine whether, in patients at risk for cardiovascular or cerebrovascular events, perioperative blood pressure monitoring or antihypertensive therapy needs to be considered.
JAMA Ophthalmology – American Medical Association
Published: Jan 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.